LeMaitre Vascular (NASDAQ:LMAT) Coverage Initiated at Wells Fargo & Company

Stock analysts at Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note issued on Thursday, Marketbeat.com reports. The brokerage set an “equal weight” rating and a $95.00 price target on the medical instruments supplier’s stock. Wells Fargo & Company‘s target price suggests a potential downside of 3.70% from the stock’s previous close.

A number of other brokerages also recently issued reports on LMAT. Barrington Research boosted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Oppenheimer restated an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Trading Up 1.7 %

LMAT opened at $98.65 on Thursday. The company has a market cap of $2.22 billion, a P/E ratio of 53.91, a P/E/G ratio of 2.19 and a beta of 0.96. The business’s 50-day moving average price is $95.99 and its 200-day moving average price is $93.49. LeMaitre Vascular has a 12 month low of $59.87 and a 12 month high of $109.58.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Conestoga Capital Advisors LLC boosted its position in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after purchasing an additional 36,850 shares in the last quarter. Copeland Capital Management LLC boosted its position in shares of LeMaitre Vascular by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock worth $107,990,000 after purchasing an additional 8,623 shares in the last quarter. State Street Corp boosted its position in shares of LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after purchasing an additional 28,525 shares in the last quarter. Congress Asset Management Co. boosted its position in shares of LeMaitre Vascular by 1.8% in the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock worth $66,555,000 after purchasing an additional 13,009 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of LeMaitre Vascular by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier’s stock worth $50,711,000 after purchasing an additional 7,737 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.